Here we show the results of BRCAN, a single center retrospective/prospective cohort study including patients diagnosed with HER2-negative early breast cancer treated with anthracycline-based chemotherapy and known BRCA1/2 status with the aim to comprehensively address the cardiac function assessed by blood biomarkers, imaging and QoL questionnaires. The gene discussed is BRCA1; the disease is breast cancer.